Latest News in the pharma Industry
Research & Development
AstraZeneca and Takeda collaborate to develop and commercialise MEDI1341 for Parkinson’s disease
31 Aug 2017
MEDI1341 has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies.
Read more
Phase III study confirms Kyprolis regimen extends overall survival In patients with relapsed multiple myeloma
31 Aug 2017
ENDEAVOR study long-term data show Kyprolis and dexamethasone reduced the risk of death by 24% versus Velcade and dexamethasone.
Read more
Lilly to file baricitinib resubmission to FDA before end of January 2018
30 Aug 2017
Resubmission package will include new safety and efficacy data.
Read more
FDA approves new antibacterial drug
30 Aug 2017
First carbapenem-based combination product – combination of meropenem with a new class of beta-lactamase inhibitor.
Read more
Krystal microplate enables development of drug testing assay
29 Aug 2017
Scientists at the NCBS using Krystal 384-well black microplates to produce a standard drug testing assay for Plasmodium vivax infection.
Read more
Berg and AstraZeneca collaborate to identify new therapeutic targets to treat neurological disorders
28 Aug 2017
Collaboration to focus on a disease target in Parkinson's disease with Berg's Interrogative Biology technology.
Read more
New Repatha data support lower LDL-C levels for high-risk cardiovascular patients
28 Aug 2017
No evidence of a leveling off of effect and no new safety concerns were identified in this analysis.
Read more
Regeneron and Sanofi to present new analyses from Praluent injection trials
27 Aug 2017
Presentations include results from ODYSSEY APPRISE, an open-label study in 16 European countries and Canada in patients with severe hypercholesterolemia at high cardiovascular risk.
Read more
EC approves first oral short-course treatment for highly active relapsing multiple sclerosis
27 Aug 2017
Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years.
Read more
FDA grants Priority Review to Genentech's emicizumab for Hemophilia A with inhibitors
24 Aug 2017
Application based on positive results of Phase III study in adults and adolescents with hemophilia A with inhibitors and interim Phase III results in children.
Read more
Novavax’ preclinical influenza nanoparticle study published in Vaccine
23 Aug 2017
Data suggest that NanoFlu has the potential to elicit a broader, more robust immune response, resulting in greater protection than the market-leading licensed influenza vaccine in older adults.
Read more
Novartis and MMV launch patient trial in Africa for a novel compound against multidrug-resistant malaria
23 Aug 2017
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission.
Read more